PHARMACOLOGY ANALYTIC

药理分析

基本信息

批准号：
8117663
负责人：
MICHELLE A RUDEK
金额：
$ 23.39万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-23 至 2012-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8117663
关键词：
Amendment Antineoplastic Agents Archives Area Arts Back Biological Biological Assay Calibration Cancer Center Clinical Clinical Trials Design Computers Consultations Core Facility Data Data Analyses Data Storage and Retrieval Databases Drug Kinetics Enzymes Equipment Floor Fluorescence Funding Funding Mechanisms Grant Health Personnel High Pressure Liquid Chromatography Housing Human Human Resources In Vitro Industry Institution Investigation Laboratories Lead Letters Link Liquid substance Location Maintenance Medical Medical History Methods Mission Monitor Names Pathology Patients Pharmaceutical Preparations Pharmacodynamics Pharmacogenetics Pharmacology Positioning Attribute Procedures Protein Binding Protocols documentation Quality Control Reagent Reporting Research Personnel Resources Retrieval Safety Sampling Services Social Security Number Solutions Staging Standardization System Temperature Testing Time Training Validation Water Writing analytical method anticancer research base computerized data processing cost data acquisition design detector drug metabolism experience falls flexibility good laboratory practice instrument mass spectrometer meetings method development operation pre-clinical preclinical study prevent protocol development quality assurance research clinical testing

项目摘要

DESCRIPTION OF SHARED RESOURCE Since the founding of the Pharmacology Analytical Core in 1985, the primary mission of the Core has been to enable the inclusion of critical pharmacological endpoints in the design of clinical trials and preclinical studies, and stimulate new hypotheses and areas of investigation by providing low-cost, state-of-the-art services. The purpose of the Core is to: 1) provide users with expertise in pharmacological trial design, analytical method development, quantitative assays, pharmacokinetic data analysis, and data interpretation in a centralized, dedicated and experienced facility; 2) provide services in real time; 3) minimize cost and effort for Cancer Center investigators; 4) prevent duplication of equipment, technical effort and analytical and pharmacokinetic analysis expertise for the Cancer Center by providing flexible assignment of personnel and equipment. The Core resource provides state-of-the-art equipment, facilities, and expertise in pharmacological trial design, analytical quantitation, and data analysis in approximately 1000 square footage of space on the first floor of the Bunting-Blaustein Cancer Research Building. The location of the Core is adequate both in size and location to meet the needs of the Cancer Center investigators to investigate drug metabolism and disposition and the pharmacodynamics and pharmacogenetics of anticancer agents.

共享资源的描述自1985年创建药理学分析核心以来，核心的主要任务一直是为了使临床试验和临床前研究设计中关键的药理终点包括并通过提供低成本，最先进的服务来刺激新的假设和调查领域。这核心的目的是：1）为用户提供药理学试验设计专业知识，分析方法在集中式的，专用和经验丰富的设施； 2）实时提供服务； 3）最小化癌症中心的成本和精力调查人员； 4）防止设备重复，技术工作以及分析和药代动力学分析通过提供人员和设备的灵活分配，为癌症中心提供专业知识。核心资源提供药理试验设计，分析定量的最先进设备，设施和专业知识，和在Bunting-Blaustein Cancer一楼的大约1000平方英尺的空间中的数据分析和数据分析研究大楼。核心的位置在大小和位置都足够满足癌症的需求中心研究人员调查药物代谢和处置以及药效学和抗癌药的药物遗传学。